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Acute bacterial meningitis is an important cause of morbidity and mortality among children
less than five years old. Haemophilus influenzae, Streptococcus pneumoniae and Neisseria
meningitidis are the most important agents of bacterial meningitis in developing countries. The
development of the conjugate vaccines in the beginning of the 90’s, especially type b H. influenzae
(Hib), and more recently the heptavalent pneumococcal and the serogroup C meningococcal vaccines,
have contributed directly to changes in the epidemiological profile of these invasive diseases
(direct effect) and of their carriage status (indirect effect). We review the impact of the Hib
conjugate vaccine in Latin American countries, where this vaccine has been implemented, and the
potential of pneumococcal and meningococcal conjugate vaccines for the reduction of meningitis
worldwide. We also address constraints for the development and delivery of these vaccines and
review new candidate state-of-the-art vaccines. The greatest challenge, undoubtedly, is to implement
these vaccines worldwide, especially in the developing regions.
Key Words: Conjugate vaccines, Hib conjugate vaccine, pneumococcal conjugate vaccine,
meningococcal conjugate vaccine, impact of Hib conjugate vaccine.
Acute bacterial meningitis is an important cause of
morbidity among children, especially in developing
countries [1,2]. Despite the increasing availability of
potent antimicrobials and sophisticated intensive care
units, mortality rates due to bacterial meningitis still
reach high levels, leading to significant neurological
sequelae [3,4].
The advent of the conjugate vaccines during the
last decade was a remarkable achievement,
launching a new era in the history of modern
vaccinology. In contrast to the first generation of the
purified polysaccharide vaccines, the conjugate
vaccines produce a T-dependent response and result
in the development of an immunological memory,
leading to clinical protection in children less than 2
years old [5,6]. This age group is at high risk for
invasive diseases caused by the three most important
agents of bacterial meningitis: Haemophilus
influenzae, Streptococcus pneumoniae  and
Neisseria meningitidis [1].
The development of a conjugate vaccine against type
b H. influenzae (Hib) in the early 1990’s, and its
implementation for routine immunization, have
contributed directly to changes in the epidemiological
profile of the invasive diseases caused by Hib in some
developed countries, especially meningitis [7,8]. More
recently, pneumococcal heptavalent conjugate vaccine
and serogroup C meningococcal conjugate vaccine
were licensed for commercial use, while the 9 to 11
valent pneumococcal vaccines are at an advanced stage
of field trials in many countries [9-13].
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Finland, Canada, Iceland, United States, United
Kingdom, Israel and Australia were the first countries to
use the Hib vaccine on a large scale at the end of the
1980’s and the beginning of the 90’s. Heath, in a review
about the efficacy of Hib vaccine in these countries,
indicated a spectacular reduction of invasive disease
incidence due to H. influenzae b [14]. In the USA, Adams
et al. observed a decrease of 82% in H. influenzae
meningitis between 1985 and 1991 based on national
surveillance data [7]. Dawson et al. [15], in a retrospective
study, detected a fall in the number of meningitis cases by
H. influenzae b, from 73% to 69%, with the
polysaccharide vaccine, and to 16%, within a 5-year-
period after the introduction of the conjugate vaccine.
In Latin America (LA), the conjugate vaccine was
first introduced into Uruguay in 1994, followed by Costa
Rica and Chile, and it is currently incorporated into the
immunization programs of almost all LA countries [16].
In Uruguay, the incidence rate of Hib meningitis fell from
15.6 to 0.03 per 100,000, 2 years after the introduction
of this vaccine [17]. In Brazil, this vaccine was first used
in Curitiba (southern Brazil) in 1996, and after a year of
routine use, a 72% reduction was observed in the
incidence of meningitis [18]. Nationwide immunization
in Brazil began in mid 1999, and after 2 years, Simões
et al. [19], in a prospective population surveillance
carried out in Goiás State (Central Brazil), demonstrated
a 78% decline in the risk of meningitis by H. influenzae
b among children under 5 years of age. Furthermore,
studies conducted in Brasília and Salvador detected a
reduction of meningitis cases of 80% and 69.9%,
respectively, after the first year of the initiation of Hib
vaccination [20,21]. The impact of Hib vaccine on
the reduction of meningitis in Latin America countries
after the introduction of the Hib vaccine in this region
ranged from 40.0% to 95.6%, depending on the time-
period of assessment (Table 1) [18-26].
The significant decline of bacterial meningitis caused
by Hib was due not only to the direct effect of this
vaccine on individual protection, but also to the
reduction of colonization of the nasopharynx [27-31],
decreasing the transmission of Hib and therefore the
incidence of meningitis by H. influenzae b in vaccine
recipients as well as in non-vaccinated children (indirect
effect of the vaccine – herd immunity) [32].
Despite the availability of the Hib conjugate vaccine
and its impressive impact on invasive diseases in
countries where it has been implemented, about 132
million children have not been treated with this vaccine,
most of them in poor countries in Africa and Asia. A
map (Figure 1) shows the current geography of Hib
vaccine implementation in the world [33].
Important obstacles have hampered the introduction
of this vaccine into the African and Asian continents.
Information about the production, the estimated costs,
the use of the vaccine on a large scale, as well as the
safety and efficacy of this vaccine are essential in these
regions. Various investigations have shown cost to be
the most critical issue to introduce the vaccination in
these countries, whereas safety and efficacy, although
significant, are less relevant. The unfavorable economic
and financial situation in many countries in Africa have
impeded increases in per capita spending on health,
making it unfeasible to introduce the Hib vaccine [34].
Most countries in Africa have limited medical and
laboratory support, making the proper identification of
etiological agents involved in invasive diseases difficult.
Moreover, other complex health problems, including
tuberculosis, malaria, HIV and meningococcal disease,
compete against H. influenzae b for priority. The public
health policy makers need to be aware of the magnitude
and the social costs of the Hib diseases, and they should
maximize efforts to incorporate this vaccine into routine
health services [35,36].
Pneumococcal Conjugate Vaccine
In comparison with Hib, Streptococcus pneumoniae
is involved in a broader range of disorders, including
invasive (pneumonia and meningitis), and non-invasive
(acute otitis media and sinusitis) diseases. It also contributes
to the highest levels of mortality and morbidity in the world,
especially in children under 5 years old [37-39]; at least
1.2 million deaths occur annually due to pneumonia, 39%
are children less than 5 years, with 100,000 to 500,000
deaths by pneumococcal meningitis [37].
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Table 1. Impact of Haemophilus influenzae b conjugate vaccine on meningitis in Latin American countries
Country Author, year Vaccine Age group Timing after Hib Coefficients x105 % Decrease
introduction vaccine introduction pre/post vaccine post vaccine
Cuba Dickinson et al. 2001 [23] 1999 < 5 years 1 year 13.6 / 7.6 52.8
Colombia Agudelo et al. 2000 [24] 1998 < 1 year 1 year - 40.0
Uruguay Ruocco et al. 1999 [17] 1994 < 5 years 2 years 15.6 / 2.7 82.7
Landaverde et al.1999 [25] 1994 All ages 6 months - 95.6
Chile Diaz et al. 2001 [26] 1996 < 5 years 2 years 36.4 / 9.9 72.7
Brazil Takemura & 1996 < 5 years 1 year 35.4 / 9.7 72.6
  Andrade 2001 [18]
Freitas 2000 [20] 1999 < 5 years 1 year - 80.0
Simões et al. 2002 [19] 1999 < 5 years 1 year 10.8 / 2.3 78.7
Ribeiro et al. 2003 [21] 1999 < 5 years 1 year 2.6 / 0.8 69.0
Source: Adapted from Simões 2002 [22].
a not reported.
b
 metropolitan area of Santiago.
c incidence in non-exposed to vaccine.
d incidence in exposed to vaccine.
e reference: Wenger et al 2000.
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Figure 1. [33]
The success achieved by Hib immunization has
stimulated the development of a pneumococcal
conjugate vaccine. In February 2000 the Food and
Drug Administration approved the use of a seven-
valent conjugate vaccine for American children under
2 years old. Among the 90 S. pneumoniae serotypes
identified so far [40], the formulation of this vaccine
contains only 7 serotypes – 4, 6B, 9V, 14, 18C, 19F
and 23F, but these are responsible for 70% to 90% of
the invasive disease cases in children in the USA,
Canada, Africa and Europe and are 70% of the
pneumococci that cause acute otitis media in USA,
Canada and Europe [41,42]. Clinical trials carried out
with the 7-valent vaccine in USA have revealed high
levels of protection against invasive pneumococcal
disease, and another review found a 50% to 60%
protection range against serotype specific
pneumococcal otitis  in Finland [43,44]. In Brazil, the
heptavalent vaccine was licensed in February 2001
[45], but it has still not been added to the PNI (national
program of immunizations) schedule. The 9-valent
conjugate vaccine contains the 7-valent serotypes, as
well as serotypes 1 and 5, and it has been evaluated
by large-scale field trials in South Africa and Gambia
[46]. The 11-valent vaccine includes the 9-valent
serotypes, as well as serotypes 3 and 7V, and it is
currently under test in clinical trials in the Philippines,
Israel, Argentina and Chile [13,38,47].
While the expected impact of the Hib conjugate vaccine
is a reduction in meningitis cases, the pneumococcal
vaccines are also expected to reduce pneumonia and acute
otitis media cases, as well as carriage prevalence, which
will significantly modify pneumococcal disease
epidemiology [48-50]. Eskola and Anttila [19] have
shown that in clinical trials with the 7-11 valent
pneumococcal conjugate vaccines, the coverage against
invasive disease, including meningitis, can reach 92%.
DiFabio et al. [51] estimated a 64.4% serotype coverage
(95% confidence interval (CI: 60.7%-67.8%) for
meningitis with the use of the heptavalent pneumococcal
vaccine in Brazil. Similar results were reported by
Brandileone et al. [52], who found that the 7-valent
vaccine would cover 61% (95% CI: 57.0%-64.9%) of
the most prevalent meningitis serotypes in Brazil in children
under 2 years old (1, 14, 19A, 19F, 5, 6A and 6B). It is
worthwhile emphasizing the high prevalence of serotypes
1 and 5 in Latin American countries, which are not included
in the heptavalent vaccine.
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The efficacy of pneumococcal vaccine against
meningitis needs to be better evaluated. So far, clinical
trials conducted in California by the Kaiser group, and
in Navajo children, did not find any case of meningitis
in the vaccinated group; however, as the number of
cases in the control group has not yet been reported
[48,53,54], it is probable that the efficacy of the
heptavalent vaccine against pneumococcal meningitis
would be better evaluated through meta-analyzes, which
have the advantage of pooling to attain a higher sample
size, increasing the power to detect significant
differences between vaccinated and unvaccinated
groups. Observational studies may also be conducted
to assess the effectiveness of the pneumococcal vaccine
during the vaccine post-licensure period.
Although there has been optimism concerning the
impact of the S. pneumoniae conjugate vaccine, there
are some restrictions against its incorporation into health
services routine, including: (i) the high cost for
implementation at a public health level, especially in
the developing world, (ii) controversy about cross-
protection against serotypes not contained in the
vaccine, and (iii) the technical difficulties of having all
pneumococcal serotypes in the same formulation.
Consequently, alternative candidates to the
pneumococcal vaccine have been tested for
immunogenicity and safety, including protein vaccines.
A large number of investigators have searched for
proteins capable of inducing immunity to invasive and
non-invasive pneumococcal infection. Pneumococcal
surface proteins, including protein A (PspA), protein
C (PspC), adhesin (PsaA) and pneumolysin, have been
considered as alternatives to promote protective
immunity in children [55,56]. These proteins can induce
protection regardless of pneumococcal serotype; for
example, PspA has been found in all isolates of S.
pneumoniae [57]. According to the amino acids
sequences, PspA can be classified into three families.
Families 1 and 2 are the main ones, and are found in
more than 98% of the PspA molecules [58,59]. Studies
conducted in animal models have showed that PspA
was the most efficacious protein for immunization
against carriage, otitis media, pneumonia and sepsis. A
synergistic effect has been detected when two proteins
are associated. A combination of PspA and
pneumolysin can induce a higher immunity to lung
infections and probably against septicemia, when
compared to PspA alone [55,60]. The relative
protective capacities of several different pneumococcal
proteins against sepsis, bacteremia, pneumonia, otitis
media and carriage suggest that the association of
different proteins optimizes protection against a broad
variety of strains and diseases. Therefore, it is plausible
that vaccines against S. pneumoniae composed of
mixtures of polysaccharides and several protein
antigens might be a better approach than a vaccine
based on a single type.
Meningococcal Conjugate Vaccine
Meningococcal meningitis is an important public
health problem worldwide, especially in sub-Saharan
Africa, where it occurs as an endemic disease, with
outbreaks every 2 years [61,62]. Neisseria meningitis
isolates can be classified into 12 groups, based on
chemically and antigenically distinct polysaccharide
capsules, but only 5 groups are responsible for almost
all meningococcal disease: A, B, C, Y and W135.
Serogroup A is responsible for epidemic disease in sub-
Saharan Africa and in developing countries in other
regions. Serogroups B and C are responsible for most
of the infections in developed countries, as well as in
developing regions. The pattern of disease caused by
serogroup B is typically hyperendemic or sporadic, in
contrast to the endemic nature of serogroup A. In the
United Kingdom, 32% of the reports of invasive
disease caused by N. meningitidis in 1996 were
associated with serogroup C [6]. Meningococcal
disease caused by serogroups Y and W135 is mainly
found in the USA [62].
The polysaccharide vaccines against serogroups A
and C, widely used for many years with relative success
in mass immunizations during outbreaks, are efficacious
in older children and in adults, but are much less
immunogenic in children under 5 years old [63]. The
development and use of meningococcal conjugate
vaccine is an alternative to polysaccharide vaccines.
The conjugate vaccines for N. meningitidis are at
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several stages of development and clinical trials.
Besides being more immunogenic than the
polysaccharides, the meningococcal conjugate vaccines
induce “herd immunity” [64]. Most of the efforts toward
the development of meningitis conjugate vaccines first
concentrated on serogroups A and C, at the end of the
1980’s. Studies conducted on children in Gambia and
the United Kingdom showed good immunogenicity and
tolerability for the bivalent conjugate vaccine A-C
[65,66]. Recently, several clinical trials made with
children and teenagers have confirmed the safety,
immunogenicity and capacity to induce
immunological memory of serogroup C
meningococcal vaccine [67-70].
In Africa, an extensive project to wipe out epidemic
meningitis has begun, based upon the utilization of two
vaccines. One of them, a heptavalent product (DTPw,
hepatitis b, Hib, meningococcal conjugate A–C), is to
be used in the expanded program of immunization, and
another product, a monovalent vaccine against
meningococcus A, will be used in the population from
1 to 29 years old [71]. Field trials with both vaccines
are scheduled to begin soon.
The United Kingdom was the first country to include
the conjugate vaccine against serogroup C in a routine
immunization program, in November 1999. After the
use of this vaccine in children and teenagers less than
19 years old, a strong reduction in serogroup C
meningococcal disease was observed [11,72,73].
Recently, Trotter et al. [74] reported that, with a
coverage of 89% vaccination, a reduction of 80% in
the incidence of meningitis by serogroup C was
detected and the number of deaths fell from 78 to 8
during the same time period.
Serogroup B meningococcus is an important
problem in the Americas and Europe due to its high
incidence in these regions, and no effective vaccine is
available to date [75,76]. The development of a
vaccine against serogroup B is a more difficult task.
The similarity between the polysaccharide structure of
the bacterial capsule and carbohydrates naturally found
in humans make this antigen auto-limited or poorly
immunogenic. Furthermore, the use of this
polysaccharide in a vaccine can stimulate the
production of auto-antibodies [77,78]. An alternative
approach to vaccine development is based on outer-
membrane vesicles. Although such vaccines induce an
antibody response and protect against meningococcal
disease, especially among children more than four years
of age [79-82], they do not protect against several
known heterologous strains [83]. On the other hand,
many previously unrecognized proteins were identified
and characterized during the genome sequencing of a
virulent strain, MC58, of meningococcus B [84,85].
Some of these proteins induce bactericidal antibodies
in serum against serogroup B meningococcus. Thus,
there is a new potential vaccine candidate, which should
be safe and capable of promoting strong homologous
and heterologous protection against N. meningitidis
B strains, although it is also likely to promote cross-
protection against other serogroups.
Final Remarks
In this epidemiological scenario post-introduction of
conjugate Hib vaccine into routine immunization
programs, the greatest challenge is to improve the current
surveillance systems. Considering the sharp decrease of
invasive disease as well as the carriage status of Hib,
more sensitive and specific diagnostic tools are essential
to the early detection of the emergence of other H.
influenzae serotypes, especially the non-typeable H.
influenzae and also the S. pneumoniae, which could
occupy the ecological niche left by Hib [86-89]. The
monitoring of possible vaccine failure [90,91], the
reemergence of cases of invasive disease by Hib, despite
adequate levels of vaccine coverage, and the antimicrobial
susceptibility of H. influenzae, including the “non-b”
strains and S. pneumoniae, are also imperative in this
post-vaccine era [92-98].
While waiting for a more effective vaccine against
all meningococcus groups, the best strategy for
meningococcal meningitis prevention is prompt large-
scale mass vaccination during the epidemic period.
Studies carried out in African countries have suggested
that an efficient surveillance system, especially for the
detection of meningococcal meningitis outbreaks, might
guide appropriate control measures, such as a mass
Meningitis Prevention and Conjugate Vaccines
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catch-up vaccination campaign, to timely decrease the
number of cases of the disease [99].
Incorporation of new epidemiological information
might be attained with the use of molecular typing
techniques for the characterization of the invasive
and colonizing serotypes, allowing systematic
evaluations of the Hib vaccine and of the forthcoming
conjugate vaccines of S. pneumoniae and N.
meningitidis, when they become widely available
and implemented.
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